Hims & Hers Slides 4.43% as Legal and Regulatory Storms Weigh on Market Leadership

Market Snapshot

Hims & Hers Health (HIMS) closed with a loss of 4.43% on 2026-04-01, amid a sharp drop in trading volume, which totaled $0.54 billion—down 22.27% from the previous day. Despite the decline in price and volume, Hims & Hers Health retained the top spot in trading activity for the day, reflecting heightened investor attention. The decline marks a continuation of a difficult stretch for the stock, following a significant 17.8% intraday drop on February 9, 2026, after the FDA announced plans to crack down on non-FDA-approved compounded GLP-1 drugs and Novo Nordisk filed a lawsuit targeting the company’s weight-loss offerings.

Key Drivers

The recent legal and regulatory developments have intensified concerns about Hims & Hers Health’s business model and product offerings. The U.S. Food and Drug Administration (FDA) announced its intent to take decisive regulatory steps to restrict the use of GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded drugs, which are being mass-marketed by companies—including Hims & Hers—as alternatives to FDA-approved medications. This announcement has raised fundamental questions about the legality and viability of the company’s compounded drug strategy, which plays a key role in its revenue generation. The FDA’s stance threatens to curtail access to these products, potentially reducing Hims & Hers’ market share in the weight-loss sector and increasing compliance costs.

Compounding concerns is a lawsuit filed by Novo Nordisk, a major player in the GLP-1 market with its FDA-approved weight-loss drugs such as Wegovy and Ozempic. Novo Nordisk has sought to bar Hims & Hers from selling compounded versions of its drugs, arguing that these alternatives pose safety risks and undermine the integrity of its FDA-approved products. This legal dispute has already led to a sharp intraday price drop in February and has now resurfaced as a focal point for investors. The lawsuit underscores the regulatory and competitive pressures facing Hims & Hers in an increasingly contentious sector.

In parallel, the Schall Law Firm has announced a securities fraud investigation into Hims & Hers Health, citing potential violations of securities laws. The investigation centers on whether the company issued false or misleading statements or failed to disclose material information to investors. This development adds to the legal overhang and could further erode investor confidence if serious allegations are substantiated. While no formal charges have been filed, the mere prospect of a class-action lawsuit has triggered volatility and raised questions about corporate governance and transparency.

Despite these challenges, Hims & Hers has seen increased institutional ownership in recent months, with several major investors—such as SG Americas Securities LLC—boosting their stakes. Institutional investors now hold approximately 63.5% of the company’s shares, indicating a degree of long-term conviction in the business. However, the recent insider selling activity—most notably by CFO Oluyemi Okupe—suggests internal uncertainty or a shift in strategic direction. These factors highlight a mixed landscape of institutional support and internal skepticism.

The company’s recent partnership with Novo Nordisk, which expanded its product offerings to include FDA-approved GLP-1 medications, was seen as a strategic pivot toward a more sustainable and legally defensible business model. This shift was intended to diversify Hims & Hers’ revenue streams and reduce its reliance on compounded drugs. However, the recent legal and regulatory pressures continue to overshadow these efforts, with analysts and investors reevaluating the stock’s long-term potential. Analysts at TD Cowen and others have recently cut their price targets or maintained “hold” ratings, reflecting a cautious stance in light of the ongoing uncertainties.

Ultimately, the stock’s recent performance appears to be driven by a combination of regulatory scrutiny, legal exposure, and strategic uncertainty. While Hims & Hers has demonstrated resilience through earnings growth and institutional support, the broader legal and regulatory risks remain the dominant factors shaping investor sentiment. The company’s ability to navigate these challenges and successfully transition to a fully FDA-compliant business will be critical in determining its long-term prospects in the competitive telehealth and pharmaceutical space.